Biotech News
Aarvik Therapeutics Welcomes Laurus Labs as Strategic Investor
Aarvik Therapeutics, an antibody-drug conjugate (ADC) biotechnology company, has secured investment from Laurus Labs, India, in its Series Seed 2 financing round. The funding, which also included multiple other investors, will support the advancement of Aarvik’s ADC pipeline. Since its
10 October 2025